EUVIMEDObjevte EUVIMED
Open access

Preclinical Evaluation of 131 I/ 18 F-Labeled Covalent Small-Molecule Inhibitors for STING Status Imaging

Jianyang Fang, Xiaobo Wang iD, Lingxin Meng, Jingru Zhang, Rongqiang Zhuang, Yesen Li, Xianzhong Zhang iD, Zhide Guo iD

ACS Pharmacology & Translational Science · 2024-06-14 · 7 (6) · 1783-1794

DOI: 10.1021/acsptsci.3c00398 ↗

At a glance

Journal article in ACS Pharmacology & Translational Science, published online on 2024-05-09. Written by Jianyang Fang and 7 co-authors. Institution: State Key Laboratory of Vaccines for Infectious Diseases, Center for Molecular Imaging and Translational Medicine, Xiang An Biomedicine Laboratory, S…. Cited 7 times so far (Crossref); 40 references. The full text is freely available in PubMed Central. Funded by: China National Nuclear Corporation, China Postdoctoral Science Foundation, National Natural Science Foundation of China.

AbstraktBibliografické údajeCiteRelated studies

Abstract (original language)

The stimulator of interferon genes (STING) is a vital protein to the immune surveillance of the tumor microenvironment. In this study, we develop novel inhibitor-based radioligands and evaluate their feasibility for noninvasive visualization of STING expression in tumor-bearing mice. Analogous compounds to STING inhibitors C170 and C176 were synthesized and labeled with 131I and 18F to attain [131I]I-NFIP and [18F]F-NFEP, respectively. The radiosynthesis was achieved with high radiochemical purity (>95%) and molar activity (28.56-48.89 GBq/μmol). The affinity and specificity of tracers were assessed through cell uptake and docking experiments, demonstrating that [131I]I-NFIP exhibited high specificity for STING, with a cell-based IC50 value of 7.56 nM. Small-animal PET/SPECT imaging and biodistribution studies in tumor-bearing mice models were performed to verify the tracers' pharmacokinetics and tumor-targeting capabilities (n = 3/group). SPECT imaging demonstrated that [131I]I-NFIP rapidly accumulated in the Panc02 tumor quickly at 30 min post-injection, with a tumor-to-muscle (T/M) ratio of 2.03 ± 0.30. This ratio significantly decreased in the blocking group (1.10 ± 0.14, **P < 0.01, n = 3). Furthermore, tumor uptake and the T/M ratio of [131I]I-NFIP were positively associated with STING expression. In summary, [131I]I-NFIP is the first STING-specific inhibitor-based radioligand offering the potential for visualizing STING status in tumors.

Authors and institutions

  • State Key Laboratory of Vaccines for Infectious Diseases, Center for Molecular Imaging and Translational Medicine, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, 4221-116 Xiang'An South Rd,…
  • Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an 71003, China.
  • Department of Nuclear Medicine and Minnan PET Center, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen 361003, China.
  • Theranostics and Translational Research Center, Institute of Clinical Medicine, Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College…

ORCID profiles: Xiaobo Wang, Xianzhong Zhang, Zhide Guo

Funding

  • China National Nuclear Corporation
  • China Postdoctoral Science Foundation
  • National Natural Science Foundation of China
  • National High-Level Hospital Clinical Research Funding

Cite

APA

Fang, J., Wang, X., Meng, L., Zhang, J., Zhuang, R., Li, Y., Zhang, X., & Guo, Z. (2024). Preclinical Evaluation of 131 I/ 18 F-Labeled Covalent Small-Molecule Inhibitors for STING Status Imaging. ACS Pharmacology & Translational Science, 7(6), 1783-1794. https://doi.org/10.1021/acsptsci.3c00398

Vancouver

Fang J, Wang X, Meng L, Zhang J, Zhuang R, Li Y, et al. Preclinical Evaluation of 131 I/ 18 F-Labeled Covalent Small-Molecule Inhibitors for STING Status Imaging. ACS Pharmacology & Translational Science. 2024;7(6):1783-1794. doi:10.1021/acsptsci.3c00398

BibTeX
@article{Fang2024,
  author = {Fang, Jianyang and Wang, Xiaobo and Meng, Lingxin and Zhang, Jingru and Zhuang, Rongqiang and Li, Yesen and Zhang, Xianzhong and Guo, Zhide},
  title = {Preclinical Evaluation of 131 I/ 18 F-Labeled Covalent Small-Molecule Inhibitors for STING Status Imaging},
  journal = {ACS Pharmacology & Translational Science},
  year = {2024},
  volume = {7},
  number = {6},
  pages = {1783--1794},
  doi = {10.1021/acsptsci.3c00398}
}
Start for free →